vrtx
VRTX424.990USD
-4.610-1.07%
종가 05/09, 16:00（ET）시세는 15분 지연됩니다
109.21B시가총액
손실P/E TTM
자세한 내용은 Vertex Pharmaceuticals Inc 회사
Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. It has seven approved medicines: five that treat the underlying cause of cystic fibrosis (CF), one that treats severe sickle cell disease (SCD) and transfusion dependent beta thalassemia (TDT), and one that treats moderate-to-severe acute pain. Its pipeline includes clinical-stage programs in CF, SCD, beta thalassemia, acute and peripheral neuropathic pain, APOL1-mediated kidney disease, IgA nephropathy and other autoimmune renal diseases and cytopenias, type 1 diabetes, myotonic dystrophy type 1, and autosomal dominant polycystic kidney disease. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (elexacaftor/tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor), and KALYDECO (ivacaftor).
회사 정보
회사 코드VRTX
회사 이름Vertex Pharmaceuticals Inc
상장일Jul 24, 1991
설립일1989
CEODr. Reshma Kewalramani
직원 수6100
유형Ordinary Share
회계 연도 종료Jul 24
주소50 Northern Avenue
도시BOSTON
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02210
전화16173416393
웹사이트https://www.vrtx.com/
회사 코드VRTX
상장일Jul 24, 1991
설립일1989
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
Mr. Jonathan Biller, J.D.
Mr. Jonathan Biller, J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
17.61K
+5.74%
Mr. Lloyd A. Carney
Mr. Lloyd A. Carney
Independent Director
Independent Director
7.12K
+12.60%
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Dr. Sangeeta N. Bhatia, M.D., Ph.D.
Independent Director
Independent Director
4.83K
+8.93%
Ms. Jennifer J. Schneider
Ms. Jennifer J. Schneider
Independent Director
Independent Director
1.72K
+86.33%
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Reshma Kewalramani
Dr. Reshma Kewalramani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
41.81K
+38.72%
Mr. Bruce I. Sachs
Mr. Bruce I. Sachs
Lead Independent Director
Lead Independent Director
40.00K
--
Dr. Carmen Bozic, M.D.
Dr. Carmen Bozic, M.D.
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
Executive Vice President - Global Medicines Development and Medical Affairs, Chief Medical Officer
32.67K
+40.46%
Dr. Ourania (Nia) Tatsis, Ph.D.
Dr. Ourania (Nia) Tatsis, Ph.D.
Executive Vice President, Chief Regulatory and Quality Officer
Executive Vice President, Chief Regulatory and Quality Officer
30.30K
+19.95%
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Dr. Jeffrey M. (Jeff) Leiden, M.D., Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
24.47K
--
Mr. Stuart A. Arbuckle
Mr. Stuart A. Arbuckle
Chief Operating Officer, Executive Vice President
Chief Operating Officer, Executive Vice President
23.68K
+38.42%
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
사업별USD
이름
수익
비율
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
지역별USD
이름
수익
비율
United States
6.68B
60.66%
Europe
3.45B
31.34%
Other
881.30M
8.00%
사업별
지역별
사업별USD
이름
수익
비율
TRIKAFTA
10.24B
92.91%
Other CF products
781.50M
7.09%
주주
업데이트 시간: Fri, May 9
업데이트 시간: Fri, May 9
주주 통계
유형
주주 통계
주주
비율
Capital World Investors
11.03%
The Vanguard Group, Inc.
9.10%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
주주 통계
주주
비율
Capital World Investors
11.03%
The Vanguard Group, Inc.
9.10%
BlackRock Institutional Trust Company, N.A.
5.45%
State Street Global Advisors (US)
4.66%
Capital Research Global Investors
4.06%
Other
65.69%
유형
주주
비율
Investment Advisor
48.67%
Investment Advisor/Hedge Fund
37.83%
Pension Fund
2.58%
Research Firm
2.34%
Bank and Trust
1.87%
Sovereign Wealth Fund
1.44%
Hedge Fund
1.43%
Individual Investor
0.13%
Insurance Company
0.11%
Other
3.60%
기관 주식 보유
업데이트 시간: Sun, Jan 19
업데이트 시간: Sun, Jan 19
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
2908
248.19M
96.64%
-1.58M
2024Q4
2877
248.76M
96.87%
-2.25M
2024Q3
2786
247.87M
96.18%
-4.19M
2024Q2
2747
248.36M
96.27%
-4.14M
2024Q1
2680
247.63M
95.87%
-4.48M
2023Q4
2608
247.92M
96.20%
-4.51M
2023Q3
2477
248.64M
96.45%
-6.19M
2023Q2
2488
248.89M
96.55%
-7.11M
2023Q1
2468
250.11M
97.13%
-4.74M
2022Q4
2454
248.59M
96.73%
-7.80M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Capital World Investors
28.33M
11.02%
+1.51M
+5.65%
Dec 31, 2024
The Vanguard Group, Inc.
23.15M
9%
+102.48K
+0.44%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
14.33M
5.57%
-90.57K
-0.63%
Dec 31, 2024
State Street Global Advisors (US)
11.98M
4.66%
+163.16K
+1.38%
Dec 31, 2024
Capital Research Global Investors
10.43M
4.06%
+1.43M
+15.85%
Dec 31, 2024
Fidelity Management & Research Company LLC
9.11M
3.54%
-1.25M
-12.07%
Dec 31, 2024
Wellington Management Company, LLP
5.92M
2.3%
+1.12M
+23.28%
Dec 31, 2024
Geode Capital Management, L.L.C.
5.65M
2.2%
-287.65K
-4.85%
Dec 31, 2024
Invesco Capital Management (QQQ Trust)
5.33M
2.07%
+71.48K
+1.36%
Feb 28, 2025
Jennison Associates LLC
4.32M
1.68%
-1.23M
-22.21%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Tue, May 6
업데이트 시간: Tue, May 6
이름
비율
VanEck Biotech ETF
10.56%
Tema Neuroscience and Mental Health ETF
9.99%
Invesco Nasdaq Biotechnology ETF
8.5%
ProShares Ultra Nasdaq Biotechnology
8.08%
iShares Biotechnology ETF
7.22%
Indexperts Gorilla Aggressive Growth ETF
6.87%
Federated Hermes MDT Large Cap Growth ETF
4.92%
Natixis Loomis Sayles Focused Growth ETF
4.69%
Franklin Genomic Advancements ETF
4.66%
First Trust NYSE Arca Biotechnology Index Fund
3.66%
더 보기
VanEck Biotech ETF
비율10.56%
Tema Neuroscience and Mental Health ETF
비율9.99%
Invesco Nasdaq Biotechnology ETF
비율8.5%
ProShares Ultra Nasdaq Biotechnology
비율8.08%
iShares Biotechnology ETF
비율7.22%
Indexperts Gorilla Aggressive Growth ETF
비율6.87%
Federated Hermes MDT Large Cap Growth ETF
비율4.92%
Natixis Loomis Sayles Focused Growth ETF
비율4.69%
Franklin Genomic Advancements ETF
비율4.66%
First Trust NYSE Arca Biotechnology Index Fund
비율3.66%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음